Clinical trial
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year
NCT01827930 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year
- Lead sponsor
- Institut Bergonié
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 31, 2009
- Completion date
- January 1, 2017
- Enrollment
- 68 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.